Efficacy of Neoadjuvant Chemohormonal Therapy for Prostate Cancer: A Meta-Analysis

A systematic review and meta-analysis of 10 studies up to August 19, 2025, evaluating neoadjuvant chemohormonal therapy combined with radical prostatectomy for locally advanced prostate cancer. The analysis, conducted by Hua Luo and shared on figshare, pools risk ratios for outcomes including biochemical progression-free survival and positive surgical margin rates. The document concludes with a GRADE assessment indicating very low certainty of evidence for survival outcomes.

Use Cases

• Compare treatment efficacy for biochemical progression-free survival based on pooled risk ratios from the meta-analysis
• Assess the impact on positive surgical margin rates based on the reported risk reduction
• Evaluate overall survival outcomes based on the distinction between randomized and non-randomized study results
• Inform clinical trial design based on the identified limitations and evidence gaps discussed in the conclusion

Strengths

• Follows PRISMA guidelines for systematic review and meta-analysis methodology
• Analyzes data from 10 distinct studies, providing a multi-study perspective
• Reports specific pooled risk ratios with 95% confidence intervals and p-values for key clinical outcomes

Limitations

• The dataset is a 26.0 KB DOCX document, which is a summary report rather than raw clinical trial data
• Row count and column-level documentation for the underlying study data are unknown
• The conclusion notes the certainty of evidence for survival outcomes is graded as very low

Provenance

Source

figshare, author Hua Luo

Collection Method

Systematic literature review and meta-analysis of studies from PubMed, Embase, Web of Science, and Cochrane databases.

Time Range

Studies included up to August 19, 2025.

Freshness

Last updated 2026-04-20 04:13:30